Connect with George Kouvas
George Kouvas, MBA

George has long experience in industrial environments where he brought complex systems to market. He is passionate about helping the community bring technical innovations to life with the goal to improve the lives of people with nervous system disorders.
George Kouvas joined the Wyss Center in February 2017 and was appointed as CTO in January 2020. With over 20 years of experience in medical devices, neurotechnology, pharma, eHealth, eBusiness and R&D services, Kouvas holds a Diploma in Electrical and Computer Engineering and an MBA, from the National Technical University of Athens (NTUA).
As CTO, George is responsible for the development and translation of the Wyss Center’s technology portfolio towards the clinic and the market. Under his leadership, one of the Wyss Center’s flagship programs, EPIOS™, evolved from initial idea to clinical-stage start-up, while other technology projects are being accelerated for human benefit.
George enjoys acting as an expert and evaluating technology innovation projects and proposals. He is passionate about helping the community bring innovations to life.
Prior to joining the Wyss Center, he was a Director and Technical leader of Merck’s eHealth platform in Switzerland, where he managed the development and market-launch of disease management solutions for several therapeutic areas. Earlier in his career he held various engineering and management roles, coordinating consortiums of technology, business and academia partners in innovation projects.
Subscribe to our updates
Updates
-
17.05.2022
Swiss Science celebrates Hansjörg Wyss
Today, Hansjörg Wyss received the Gallatin Award from the Swiss American Chamber of Commerce for his great commitments to the science landscape in Switzerland.
Wyss Center -
22.03.2022
Completely locked-in man uses brain-computer interface to communicate
Two-year study paves the way for new technologies for people with severe paralysis
Technology -
24.02.2022
GliaPharm SA and the Wyss Center enter collaboration to develop new therapies for Alzheimer’s disease
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Collaboration